It is well known that Chitosan oligosaccharide is low molecular weight and water soluble and chitosan oligosaccharide has been shown to reduce blood cholesterol and blood pressure, increase immunity, and enhance antitumor properties. the effect of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with normal blood glucose, impaired fasting glucose and impaired glucose tolerance.

A randomized, double-blinded, controlled, cross-over trial was conducted to verify the effects of chitosan oligosaccharide (GO2KA1). forty healthy male and female subjects aged 20-75 years with normal blood glucose, impaired fasting glucose and impaired glucose tolerance were recruited. The subjects visited the research site twice over with a seven-day interval after an overnight fast at least 12 hr. On the screening visit, the participants were the 2-hr oral glucose tolerance test (OGTT) was conducted. And they were separated normal blood glucose, impaired fasting glucose and impaired glucose tolerance. On the first visit, the participants were randomly assigned to consume a test or placebo product [test product: chitosan oligosaccharide powder 500mg (GO2KA1); placebo product: white egg powder 500mg] and ingested the assigned product. On the second visit, the participants consumed the other product that they did not eat on the first visit. On both visit day, the 2-hr oral sucrose tolerance test (OSTT) was conducted and started at 8:00 in the morning; venous blood samples were collected before (0 hr) and after ingestion (0.5, 1 and 2 hr) of the products.

Inclusion Criteria:

• Normal Blood Glucose (fasting blood sugar below 100mg/dl, two hours after meals below 140mg/dl)
• Impaired Fasting Glucose (fasting blood sugar 100-125mg/dl)
• Impaired Glucose Tolerance (two hours after meals 140-199mg/dl)

Exclusion Criteria:

• history/presence of diabetes mellitus (including oral hypoglycaemic agent and insulin)
• history of serious hypoglycemia
• history of serious cardiovascular, cerebrovascular disease, pulmonary, gastrointestinal, hepatic, renal and/or haematological disease
• uncontrolled blood pressure (blood pressure level more than 140/90mmHg)
• history/presence of alcoholism, drug addiction, etc.
• taking a regulation of blood glucose medications within 1 month before study
• participation other intervention studies within 1 months before study
• history of diagnosed with cancer, cancer surgery and hospitalization
• women who are pregnant or desire to become pregnant during the study period
• having any other medical condition which, in the opinion of the investigator, could interfere with participation in the study